Orderable - KRAS NGS

Turnaround Time: 15 days

Alternate Name(s):

ERAS
NRAS

Specimen:

FFPE

Collection Information:

Send blocks to pathology lab for cutting

Reference Ranges:

See report

Interpretive Comments:

The presence of K-ras gene (KRAS) and N-ras gene (NRAS) mutation has been shown to be associated with lack of clinical response to therapies targeted at EGFR, such as cetuximab and panitumumab. While clinical guidelines for RAS mutational analysis are evolving, recent evidence and guidelines suggest that all patients with stage IV colorectal carcinoma who are candidates for anti-EGFR antibody therapy should have their tumor tested for KRAS and NRAS mutations. Anti-EGFR antibody therapy is not recommended for patients whose tumors show mutations in KRAS codons 12, 13, 59, 61, 117 or 146, or NRAS codons 12, 13, 59 or 61. Current evidence suggests that the presence of BRAF mutation is suggestive of poor prognosis in colorectal cancer; however whether or not it is predictive of lack of clinical response to anti-EGFR monoclonal antibody therapies remains controversial. (PMID:2402483, 24687833, 25115304, 24996433)
KRAS

NRAS and BRAF for colon cancer. This assay has been internally validated to meet >99% sensitivity and specificity for mutations that are at 5% mutant allele frequency in the assessed DNA sample. Rarely, mutations are detected at <5% mutant allele frequency and these are confirmed using alternate methodology, including real-time quantitative PCR.

Storage and Shipment:
Deliver to lab at room temperature.

Test Schedule:
As required, Monday to Friday 0800-1600 hours